Table 3. Baseline Characteristics per Conservative Treatment or Future Parathyroidectomy.
| Variablea | Individuals, No. (%) | SMD | |
|---|---|---|---|
| Conservative treatment | Parathyroidectomy | ||
| No. of patients | 9440 | 6934 | NA |
| Age, mean (SD), y | 71.1 (12.5) | 62.6 (11.6) | −0.710 |
| Female sex | 7418 (78.6) | 5388 (77.7) | −0.021 |
| Male sex | 2022 (21.4) | 1546 (22.3) | 0.021 |
| Urban residency, ≥200 per km2 | 2768 (29.3) | 2006 (28.9) | −0.009 |
| Sickness benefits | 815 (8.6) | 1394 (20.1) | 0.331 |
| Non-Nordic citizenship at birth | 829 (8.8) | 613 (8.8) | 0.002 |
| Charlson Comorbidity Index | |||
| Mean (SD) | 1.18 (1.76) | 0.58 (1.19) | −0.403 |
| 0 | 4869 (51.6) | 4954 (71.4) | 0.417 |
| 1 or 2 | 3060 (32.4) | 1576 (22.7) | −0.218 |
| ≥3 | 1511 (16.0) | 404 (5.8) | −0.331 |
| Diagnosesb | |||
| Osteoporosis | 836 (8.9) | 368 (5.3) | −0.139 |
| Previous alcohol-related disease | 111 (1.2) | 77 (1.1) | −0.006 |
| Rheumatoid arthritis | 251 (2.7) | 127 (1.8) | −0.056 |
| Previous fracture | |||
| Any | 1641 (17.4) | 843 (12.2) | −0.148 |
| Recent (past year) | 688 (7.3) | 306 (4.4) | −0.123 |
| Multiple (≥2 occasions) | 354 (3.8) | 145 (2.1) | −0.099 |
| Previous injurious fall | |||
| Any | 920 (9.7) | 492 (7.1) | −0.096 |
| Recent (past year) | 352 (3.7) | 125 (1.8) | −0.118 |
| Multiple (≥2 occasions) | 128 (1.4) | 48 (0.7) | −0.066 |
| Dementia | 306 (3.2) | 19 (0.3) | −0.227 |
| Ischemic heart disease | 1225 (13.0) | 421 (6.1) | −0.237 |
| Myocardial infarction | 359 (3.8) | 96 (1.4) | −0.153 |
| Cerebrovascular disease | |||
| Any | 728 (7.7) | 199 (2.9) | −0.218 |
| Previous hemorrhagic stroke | 52 (0.6) | 12 (0.2) | −0.063 |
| Previous ischemic stroke | 356 (3.8) | 101 (1.5) | −0.145 |
| CHD | 891 (9.4) | 145 (2.1) | −0.319 |
| Diabetes | 1228 (13.0) | 492 (7.1) | −0.198 |
| Kidney failure | 552 (5.8) | 164 (2.4) | −0.176 |
| Previous kidney stone | 437 (4.6) | 547 (7.9) | 0.135 |
| COPD | 844 (8.9) | 310 (4.5) | −0.179 |
| Hyperthyroidism | 254 (2.7) | 115 (1.7) | −0.071 |
| Medications used in past yearc | |||
| Osteoporosis drugs | 711 (7.5) | 368 (5.3) | −0.091 |
| Calcium and vitamin D | 502 (5.3) | 160 (2.3) | −0.158 |
| Prednisolone | 1124 (11.9) | 513 (7.4) | −0.153 |
| Opioids | 1184 (12.5) | 585 (8.4) | −0.134 |
| Antiepileptics | 389 (4.1) | 187 (2.7) | −0.079 |
| Antiparkinson drugs | 207 (2.2) | 66 (1.0) | −0.100 |
| Antidepressants | 1568 (16.6) | 899 (13.0) | −0.103 |
| Antidementia drugs | 128 (1.4) | 19 (0.3) | −0.121 |
| Thiazide diuretics | 565 (6.0) | 308 (4.4) | −0.069 |
| β-blockers | 3072 (32.5) | 1464 (21.1) | −0.260 |
| Calcium antagonist | 1906 (20.2) | 1054 (15.2) | −0.131 |
| RAS inhibitors | 3465 (36.7) | 1854 (26.7) | −0.215 |
Abbreviations: CHD, congestive heart disease; COPD, chronic obstructive pulmonary disease; NA, not applicable; RAS, renin-angiotensin system; SMD, standardized mean difference.
a
Detailed definitions of variables are provided in eTable 1 in the Supplement.
b
A 5-year historical window was used for diagnoses, if not otherwise stated.
c
Medications used in the past year were defined by a prescription during the past year, were repeated (≥2 prescriptions), and were ongoing (most recent prescription collected <120 days before baseline).